Margaretha M. Visser

Leuven, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

The Correlation Between Fear and Perceived Frequency of Hypoglycemia and Continuous Glucose Monitoring Metrics in Adults With Type 1 Diabetes Using Diabetes Technology: A One-Year Analysis.

The Correlation Between Fear and Perceived Frequency of Hypoglycemia and Continuous Glucose Monitoring Metrics in Adults With Type 1 Diabetes Using Diabetes Technology: A One-Year Analysis.

Journal: Diabetes care

Published: March 31, 2026

Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.

Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.

Journal: Diabetes technology & therapeutics

Published: December 30, 2025

Trends in baseline HbA1c and body-mass index in randomised trials of people with type 1 diabetes from 1993 to 2025: an IMI2 SOPHIA systematic review and meta-analysis.

Trends in baseline HbA1c and body-mass index in randomised trials of people with type 1 diabetes from 1993 to 2025: an IMI2 SOPHIA systematic review and meta-analysis.

Journal: EClinicalMedicine

Published: March 20, 2025

Review Article - Diabetes Technology in the Hospital: An Update.

Review Article - Diabetes Technology in the Hospital: An Update.

Journal: Current diabetes reports

Published: May 29, 2024

Best practices in collecting and reporting continuous glucose monitoring data in research settings.

Best practices in collecting and reporting continuous glucose monitoring data in research settings.

Journal: Nature metabolism

Published: February 15, 2024

The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study.

The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study.

Journal: Diabetologia

Published: January 26, 2024

Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium.

Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium.

Journal: Diabetologia

Published: July 05, 2023

The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 Trial.

The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 Trial.

Journal: Journal of diabetes science and technology

Published: September 29, 2022

Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial.

Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial.

Journal: The lancet. Diabetes & endocrinology

Published: September 28, 2022

Diabetic Ketoacidosis After Sodium-Glucose Cotransporter Inhibitor Initiation Under Advanced Hybrid Closed-Loop Therapy in Type 1 Diabetes.

Diabetic Ketoacidosis After Sodium-Glucose Cotransporter Inhibitor Initiation Under Advanced Hybrid Closed-Loop Therapy in Type 1 Diabetes.

Journal: Diabetes technology & therapeutics

Published: February 14, 2022

Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.

Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.

Journal: Lancet (London, England)

Published: February 19, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026